| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
Purity: ≥97.00%
| Targets |
Azido-PEG2-NHS ester is classified as an ADC linker and a click chemistry reagent. The NHS ester reacts with primary amines on proteins, peptides, and other amine-containing molecules. The azide group enables click chemistry reactions with alkyne-containing molecules.
|
|---|---|
| ln Vitro |
Azido-PEG2-NHS ester is used as a linker in the synthesis of antibody-drug conjugates (ADCs). It is not typically evaluated for direct biological activity as a standalone compound. Its role is to provide a PEG spacer and reactive groups for conjugation.
|
| ln Vivo |
Azido-PEG2-NHS ester is not typically evaluated for in vivo activity as a standalone compound. Its role is in the synthesis of ADCs, which are then evaluated in vivo. The PEG spacer can improve the pharmacokinetic properties of the conjugated molecules.
|
| Enzyme Assay |
Azido-PEG2-NHS ester is a chemical reagent, and its purity and identity are confirmed using analytical techniques such as NMR and HPLC. It is not typically used in enzyme or receptor binding assays. The NHS ester reactivity can be assessed by reacting it with amine-containing compounds.
|
| Cell Assay |
Azido-PEG2-NHS ester is not typically used in cell-based assays as a standalone compound. Its primary application is in the synthesis of ADCs, which are then tested in cell-based assays for their cytotoxicity and target specificity.
|
| Animal Protocol |
Azido-PEG2-NHS ester is not typically used in in vivo animal studies as a standalone compound. It is used to synthesize ADCs, which are then evaluated in animal models for their antitumor efficacy and safety.
|
| ADME/Pharmacokinetics |
Azido-PEG2-NHS ester has a molecular formula of C11H16N4O6 and a molecular weight of 300.27. It is a non-cleavable heterobifunctional crosslinker with a PEG2 spacer. It contains an azide group and an NHS ester.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Azido-PEG2-NHS ester are not detailed in the available literature. As a linker used in ADC synthesis, its toxicity is typically assessed as part of the final ADC product. Standard safety precautions should be taken when handling this compound.
|
| Additional Infomation |
Azido-PEG2-NHS ester is a non-cleavable PEG linker used in the synthesis of antibody-drug conjugates (ADCs). It is a click chemistry reagent containing an azide group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with alkyne-containing molecules. It is a research tool for the development of targeted cancer therapies.
|
| Molecular Formula |
C11H16N4O6
|
|---|---|
| Molecular Weight |
300.2679
|
| Exact Mass |
300.106
|
| CAS # |
1312309-64-0
|
| Related CAS # |
1108750-59-9
|
| PubChem CID |
59289487
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
-1.87
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
21
|
| Complexity |
418
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])N=[N+]=[N-])=O)N1C(C([H])([H])C([H])([H])C1=O)=O
|
| InChi Key |
XDXWXTIRKQZRNN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H16N4O6/c12-14-13-4-6-20-8-7-19-5-3-11(18)21-15-9(16)1-2-10(15)17/h1-8H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-(2-azidoethoxy)ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~333.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3303 mL | 16.6517 mL | 33.3034 mL | |
| 5 mM | 0.6661 mL | 3.3303 mL | 6.6607 mL | |
| 10 mM | 0.3330 mL | 1.6652 mL | 3.3303 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA